非類固醇消炎劑（NSAID）原料藥市場規模、佔有率和成長分析：按化學分類、來源、藥物純度/等級、應用和地區分類－2026-2033年產業預測

2024 年，全球非類固醇消炎劑(NSAIDs)原料藥市場價值為 260 億美元，預計到 2033 年將從 2025 年的 275.6 億美元成長至 439.3 億美元，預測期（2026-2033 年）的複合年成長率為 6.0%。

全球非類固醇消炎劑（NSAID）原料藥市場的主要驅動力是NSAID需求的成長，而人口老化和慢性發炎及肌肉骨骼疾病盛行率的上升又進一步推動了NSAID需求的成長。該市場向非專利藥生產商供應Ibuprofen、萘普生和雙氯芬酸等活性藥物成分，對第一線鎮痛藥的成本、品質和可及性產生顯著影響。專利到期以及由此導致的學名藥供應增加，正促使產業格局從垂直整合的製藥公司轉向主要位於印度和中國的原料藥生產商。受一般化和監管措施驅動的成本趨勢在塑造市場成長方面發揮著至關重要的作用。人工智慧透過加速藥物發現週期和最佳化流程，提高了研發效率，促進了更環保、更有效率的生產方法的開發，最終增強了市場韌性並擴大了產能。

全球非類固醇消炎劑（NSAID）原料藥市場成長要素

全球非類固醇消炎劑(NSAID) 市場的主要促進因素之一是慢性發炎性疾病和疼痛相關疾病的日益普遍。隨著全球人口老化和文明病盛行率的上升，對有效疼痛管理方案的需求不斷成長。此外，人們對 NSAID 在治療關節炎、骨關節炎和其他肌肉骨骼疾病方面的益處認知不斷提高，也進一步推動了市場成長。醫療基礎設施的完善和先進 NSAID 製劑的普及也促進了這些藥物的廣泛應用，使其成為疼痛緩解治療中不可或缺的一部分。

全球非類固醇消炎劑（NSAID）市場面臨的限制因素

全球非類固醇消炎劑(NSAID) 市場的主要限制因素之一是長期服用此類藥物帶來的副作用發生率增加。患者常常會出現胃腸道問題、心血管風險和腎臟問題，這些都會影響患者的用藥依從性，並限制 NSAID 在疼痛管理和發炎控制中的應用。此外，消費者對生物製藥和天然補充劑等替代療法的認知度不斷提高，也可能降低他們對 NSAID 的偏好。監管機構對 NSAID 處方的監管和謹慎性指導方針進一步加劇了這些擔憂，從而抑制了 NSAID 在醫療保健領域的整體市場成長和滲透率。

全球非類固醇消炎劑（NSAIDs）原料藥。

全球非類固醇消炎劑（NSAID）原料藥市場正呈現出顯著的創新趨勢，尤其是在製劑和給藥技術方面。這主要得益於生產者致力於改善治療效果和提高病患依從性。緩釋基質、經皮吸收貼片和緩釋製劑等先進給藥機制的引入，促進了藥物研發人員與輔料專家之間的合作。這一趨勢不僅使現有原料藥能夠重新定位到特定治療領域，還有助於延長產品生命週期，同時避免價格競爭。以患者為中心的設計和簡化的給藥方法，正在推動策略夥伴關係和精準行銷，最終影響不同市場中處方醫生的偏好和支付方的認知。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球非類固醇消炎劑（NSAIDs）原料藥（API）市場規模：依化學分類

• 丙酸衍生物
• 乙酸衍生物
• 烯醇酸衍生物
• 選擇性COX-2抑制劑

全球非類固醇消炎劑(NSAIDs)原料藥(API) 市場規模：按製造商分類

• 內部生產
• 契約製造

全球非類固醇消炎劑（NSAIDs）原料藥（API）市場規模：依藥物純度和等級分類。

• USP/EP 標準級
• 高純度研究級

全球非類固醇消炎劑（NSAIDs）原料藥（API）市場規模：按應用分類。

• 片劑和膠囊劑型
• 外用凝膠和貼劑
• 注射藥物

全球非類固醇消炎劑（NSAIDs）原料藥（API）市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Pfizer Inc.
• Bayer AG
• Johnson & Johnson
• Amgen Inc.
• Merck & Co., Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Sanofi SA
• GlaxoSmithKline plc
• AbbVie Inc.
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd.
• Mylan NV
• Zydus Cadila
• Dr. Reddy's Laboratories
• Lupin Pharmaceuticals
• Sandoz International GmbH

結論與建議

Global Nonsteroidal Anti-Inflammatory Apis Market size was valued at USD 26.0 Billion in 2024 and is poised to grow from USD 27.56 Billion in 2025 to USD 43.93 Billion by 2033, growing at a CAGR of 6.0% during the forecast period (2026-2033).

The global nonsteroidal anti-inflammatory APIs market is primarily driven by the increasing demand for NSAID medications, spurred by population aging and the rising incidence of chronic inflammatory and musculoskeletal disorders. This market, which supplies active pharmaceutical ingredients like ibuprofen, naproxen, and diclofenac to generic formulators, significantly impacts the cost, quality, and availability of frontline analgesics. The industry has transitioned from vertically integrated pharmaceutical companies to API manufacturers predominantly in India and China due to patent expirations and subsequent generic supply increases. Cost dynamics, driven by genericization and regulatory scrutiny, play a crucial role in shaping market growth. AI is enhancing R&D efficiency by expediting discovery cycles and optimizing processes, fostering the development of greener, more efficient production methods, ultimately bolstering market resilience and capacity expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nonsteroidal Anti-Inflammatory Apis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nonsteroidal Anti-Inflammatory Apis Market Segments Analysis

Global nonsteroidal anti-inflammatory apis market is segmented by chemical class, manufacturing source, drug purity/grade, application type and region. Based on chemical class, the market is segmented into Propionic Acid Derivatives, Acetic Acid Derivatives, Enolic Acid Derivatives and Selective COX-2 Inhibitors. Based on manufacturing source, the market is segmented into In-house Manufacturing and Contract Manufacturing. Based on drug purity/grade, the market is segmented into USP/EP Standard Grade and High-Purity Research Grade. Based on application type, the market is segmented into Tablet & Capsule Formulations, Topical Gels & Patches and Injectable Solutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nonsteroidal Anti-Inflammatory Apis Market

One of the key market drivers for the global nonsteroidal anti-inflammatory drugs (NSAIDs) market is the rising prevalence of chronic inflammatory conditions and pain-related disorders. As the global population ages and lifestyle-related diseases increase, there is a heightened demand for effective pain management solutions. Additionally, the growing awareness of the benefits of NSAIDs for treating conditions such as arthritis, osteoarthritis, and other musculoskeletal disorders further propels market growth. The expansion of healthcare infrastructure and the increasing availability of advanced NSAID formulations also contribute to the growing adoption of these medications, making them a critical component of pain relief therapies.

Restraints in the Global Nonsteroidal Anti-Inflammatory Apis Market

One key market restraint for the global nonsteroidal anti-inflammatory agents (NSAIDs) market is the increasing incidence of adverse effects associated with long-term use of these medications. Patients often experience gastrointestinal issues, cardiovascular risks, and kidney problems, which can hinder patient compliance and limit the use of NSAIDs in managing pain and inflammation. Additionally, growing awareness among consumers of alternative therapies, such as biologics or natural supplements, may shift preferences away from NSAIDs. Regulatory scrutiny and guidelines urging caution in NSAID prescriptions further exacerbate these concerns, thereby restraining overall market growth and penetration in the healthcare landscape.

Market Trends of the Global Nonsteroidal Anti-Inflammatory Apis Market

The Global Nonsteroidal Anti-Inflammatory APIs market is witnessing a significant trend towards formulation and delivery innovation, driven by manufacturers aiming to enhance therapeutic profiles and improve patient adherence. The introduction of advanced delivery mechanisms such as controlled release matrices, transdermal patches, and modified release constructs fosters collaboration between drug developers and excipient specialists. This trend not only allows for the repositioning of established APIs into niche therapeutic areas but also helps extend product lifecycles without succumbing to price competition. A focus on patient-centered design and simplified administration methods is encouraging strategic partnerships and targeted marketing, ultimately influencing prescriber preferences and payer recognition across diverse markets.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Nonsteroidal Anti-inflammatory APIs Market Size by Chemical Class & CAGR (2026-2033)

• Market Overview
• Propionic Acid Derivatives
• Acetic Acid Derivatives
• Enolic Acid Derivatives
• Selective COX-2 Inhibitors

Global Nonsteroidal Anti-inflammatory APIs Market Size by Manufacturing Source & CAGR (2026-2033)

• Market Overview
• In-house Manufacturing
• Contract Manufacturing

Global Nonsteroidal Anti-inflammatory APIs Market Size by Drug Purity/Grade & CAGR (2026-2033)

• Market Overview
• USP/EP Standard Grade
• High-Purity Research Grade

Global Nonsteroidal Anti-inflammatory APIs Market Size by Application Type & CAGR (2026-2033)

• Market Overview
• Tablet & Capsule Formulations
• Topical Gels & Patches
• Injectable Solutions

Global Nonsteroidal Anti-inflammatory APIs Market Size & CAGR (2026-2033)

• North America (Chemical Class, Manufacturing Source, Drug Purity/Grade, Application Type)
  • US
  • Canada
• Europe (Chemical Class, Manufacturing Source, Drug Purity/Grade, Application Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Chemical Class, Manufacturing Source, Drug Purity/Grade, Application Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Chemical Class, Manufacturing Source, Drug Purity/Grade, Application Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Chemical Class, Manufacturing Source, Drug Purity/Grade, Application Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations